Form 4: SCYNEXIS Director Ann Hanham Acquires Equity Compensation

SCYNEXIS Inc. Director Ann Hanham acquired 23,000 shares of common stock and 23,000 stock options on June 26, 2025, as part of her compensation package.

Summary

• Ann Hanham, a Director of SCYNEXIS Inc. (SCYX), acquired 23,000 shares of common stock and 23,000 stock options on June 26, 2025.
• The common stock acquisition was for 23,000 shares at a price of $0, indicating a grant of restricted stock units.
• These restricted stock units are scheduled to vest 100% on the first anniversary of the grant date (June 26, 2025), contingent on continuous service as a non-employee director.
• Following this transaction, Ann Hanham directly beneficially owns 69,622 shares of common stock.
• The stock options were granted with an exercise price of $0.74 per share.
• These stock options are also scheduled to vest 100% on the first anniversary of the grant date (June 26, 2025), contingent on continuous service.
• The acquired stock options have an expiration date of June 25, 2035.
• Following this transaction, Ann Hanham directly beneficially owns 23,000 stock options.

Sentiment

Score: 7

Explanation: The filing indicates a standard equity grant to a director, which is generally positive as it aligns interests, but it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• Director Ann Hanham's acquisition of shares and stock options aligns her interests with those of shareholders, promoting long-term value creation.
• The equity grants are part of a standard compensation structure designed to attract and retain qualified non-employee directors.

Risks

• Vesting of both the restricted stock units and stock options is contingent on Ann Hanham providing continuous services as a non-employee director for one year from the grant date.

Future Outlook

The vesting schedule for the newly acquired restricted stock units and stock options indicates a future milestone on June 26, 2026, contingent on the director's continued service.

Industry Context

This Form 4 filing reflects a standard practice in corporate governance where non-employee directors receive equity compensation, such as restricted stock units and stock options, to align their interests with long-term shareholder value. This is common across various industries, particularly in biotechnology and pharmaceuticals, where long-term commitment is valued.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a non-employee director is a common compensation practice across publicly traded companies, including those in the biotechnology sector like SCYNEXIS.
• The specific amounts and vesting schedules are typically determined by the company's compensation committee based on peer group analysis and industry benchmarks for director compensation, though specific comparable companies or projects are not detailed in this filing.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging long-term value creation.

Next Steps

• The restricted stock units and stock options are scheduled to vest on June 26, 2026, provided continuous service by the director.

Key Dates

Recommendation

Keywords

SCYNEXIS, SCYX, Form 4, Insider Transaction, Director Compensation, Equity Grant, Stock Options, Restricted Stock Units, Beneficial Ownership